Shinichi Oikawa

ORCID: 0000-0003-2160-3807
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lipoproteins and Cardiovascular Health
  • Diabetes, Cardiovascular Risks, and Lipoproteins
  • Lipid metabolism and disorders
  • Regulation of Appetite and Obesity
  • Adipose Tissue and Metabolism
  • Cancer, Lipids, and Metabolism
  • Adipokines, Inflammation, and Metabolic Diseases
  • Diet and metabolism studies
  • Metabolism, Diabetes, and Cancer
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Diabetes Treatment and Management
  • Biochemical Analysis and Sensing Techniques
  • Fatty Acid Research and Health
  • Liver Disease Diagnosis and Treatment
  • Growth Hormone and Insulin-like Growth Factors
  • Diet, Metabolism, and Disease
  • Pancreatic function and diabetes
  • Antioxidant Activity and Oxidative Stress
  • Head and Neck Cancer Studies
  • Peroxisome Proliferator-Activated Receptors
  • Atherosclerosis and Cardiovascular Diseases
  • Diabetes Management and Research
  • Cholesterol and Lipid Metabolism
  • Adrenal and Paraganglionic Tumors
  • Diabetes and associated disorders

Nippon Medical School
2014-2025

Fukujuji Hospital
2016-2025

Japan Anti Tuberculosis Association
2016-2025

Iwate Medical University
2016-2025

Nippon Seiki (Japan)
2021

Japanese Red Cross Akita College of Nursing
2021

University of Tokyo Hospital
2016

Teikyo University Hospital
2016

International University of Health and Welfare
2016

Nippon Medical School Hospital
2010-2014

In 1999, the Japan Diabetes Society (JDS) launched previous version of diagnostic criteria diabetes mellitus, in which JDS took initiative adopting glycated hemoglobin (HbA1c) as an adjunct to diagnosis diabetes. contrast, 2009 International Expert Committee composed members American Association (ADA) and European for Study (EASD) manifested recommendation regarding use HbA1c diagnosing mellitus alternative glucose measurements based on updated evidence showing that has several advantages a...

10.1111/j.2040-1124.2012.00207.x article EN other-oa Journal of Diabetes Investigation 2012-02-01

Mulberry 1-deoxynojirimycin (DNJ), a potent glucosidase inhibitor, has been hypothesized to be beneficial for the suppression of abnormally high blood glucose levels and thereby prevention diabetes mellitus. However, DNJ contents in commercial mulberry products were as low about 0.1% (100 mg/100 g dry product), implying that bioavailability might not expected. We carried out studies two directions: (1) production food-grade powder containing maximally content; (2) determination optimal dose...

10.1021/jf062680g article EN Journal of Agricultural and Food Chemistry 2007-06-08

Prevention of atherosclerotic cardiovascular diseases is an important public health priority in Japan due to aging population.To determine whether daily, low-dose aspirin reduces the incidence events older Japanese patients with multiple risk factors.The Primary Project (JPPP) was a multicenter, open-label, randomized, parallel-group trial. Patients (N = 14,464) were aged 60 85 years, presenting hypertension, dyslipidemia, or diabetes mellitus recruited by primary care physicians at 1007...

10.1001/jama.2014.15690 article EN JAMA 2014-11-17

Background: Evidence regarding the primary prevention of coronary artery disease events by low-density lipoprotein cholesterol (LDL-C) lowering therapy in older individuals, aged ≥75 years, is insufficient. This trial tested whether LDL-C–lowering with ezetimibe useful for cardiovascular patients. Methods: multicenter, prospective, randomized, open-label, blinded end-point evaluation conducted at 363 medical institutions Japan examined preventive efficacy patients elevated LDL-C without...

10.1161/circulationaha.118.039415 article EN Circulation 2019-08-22

Growth hormone secretagogues (GHSs) stimulate GH secretion and food intake. GHS receptor (GHS-R) mRNA has been identified mainly in the arcuate nucleus (Arc) ventromedial of hypothalamus pituitary. Ghrelin, an endogenous ligand for GHS-R, recently purified from rat stomach. Although ghrelin is also expressed hypothalamus, physiological significance ghrelin/GHS-R system still unknown. We have created transgenic (Tg) rats expressing antisense GHS-R under control promoter tyrosine hydroxylase...

10.1172/jci13300 article EN Journal of Clinical Investigation 2002-06-01

Hyperlipidemia is a well-established risk factor for primary coronary heart disease (CHD). Although simvastatin known to lower serum lipid concentrations, the protective effect of such lipid-lowering therapy against CHD has not been established in Japanese patients with hypercholesterolemia. The Japan Lipid Intervention Trial was 6-year, nationwide cohort study 47,294 treated open-labeled (5-10 mg/day) and monitored by physicians under standard clinical conditions. aim determine relationship...

10.1253/circj.66.1087 article EN Circulation Journal 2002-01-01

Growth hormone secretagogues (GHSs) stimulate GH secretion and food intake. GHS receptor (GHS-R) mRNA has been identified mainly in the arcuate nucleus (Arc) ventromedial of hypothalamus pituitary. Ghrelin, an endogenous ligand for GHS-R, recently purified from rat stomach. Although ghrelin is also expressed hypothalamus, physiological significance ghrelin/GHS-R system still unknown. We have created transgenic (Tg) rats expressing antisense GHS-R under control promoter tyrosine hydroxylase...

10.1172/jci0213300 article EN Journal of Clinical Investigation 2002-06-01

Aim: The Japan EPA Lipid Intervention Study (JELIS) was the first prospective randomized clinical trial to demonstrate prevention of coronary events by pure eicosapentaenoic acid (EPA). aim this study examine relationships between various plasma fatty concentrations and risk in JELIS participants.Methods: In 15,534 participants, we calculated hazard ratio for major (sudden cardiac death, fatal or nonfatal myocardial infarction, unstable angina pectoris, angioplasty/stenting artery bypass...

10.5551/jat.5876 article EN cc-by-nc-sa Journal of Atherosclerosis and Thrombosis 2011-01-01

Background and Purpose— The JELIS trial examined the preventive effect of eicosapentaenoic acid (EPA) against coronary artery diseases. Hypercholesterolemic patients received statin only (no EPA group: n=9319) or with (EPA n=9326) for around 5 years. significantly suppressed incidence events in previous analysis. Herein, we investigated effects on primary secondary prevention stroke. Methods— We conducted a subanalysis respect to stroke subgroups defined as those without prior history using...

10.1161/strokeaha.107.509455 article EN Stroke 2008-05-04

Risk factors for cardiovascular complications in Japanese patients with diabetes have not been fully elucidated.Our objective was to determine incidence of and risk coronary heart disease (CHD) stroke diabetic patients.We conducted a prospective study at 59 hospitals throughout Japan.Patients included 940 men 831 women type 2 (mean age, 58.2 yr) without history who were followed median 7.86 yr.This an observational study.Incidence CHD evaluated.Incidences per 1000 person-years 9.59 7.45,...

10.1210/jc.2011-0622 article EN The Journal of Clinical Endocrinology & Metabolism 2011-08-25

Familial hypercholesterolemia (FH) is a highly prevalent autosomal dominant hereditary disease, generally characterized by three major signs, hyper-low-density-lipoprotein (LDL) cholesterolemia, tendon/skin xanthomas and premature coronary artery disease (CAD). Because the risk of CAD very high in these patients, they should be identified at an early stage their lives started on intensive treatment to control LDL-cholesterol. We here introduce new guideline for management FH patients Japan...

10.5551/jat.14621 article EN cc-by-nc-sa Journal of Atherosclerosis and Thrombosis 2012-01-01

Background: Results from JELIS (Japan EPA Lipid Intervention Study) demonstrated the efficacy of pure eicosapentaenoic acid (EPA) in preventing coronary artery disease (CAD) hypercholesterolemic patients under statin treatment. The present study examined detail whether is effective for secondary prevention CAD. Methods and Results: Patients with established CAD a total cholesterol level ≥250 mg/dl were observed mean follow-up 4.6 years. They randomly assigned to receive either 1,800 mg +...

10.1253/circj.cj-08-1197 article EN Circulation Journal 2009-01-01

This paper described the Guideline for Diagnosis and Management of Hyperlipidemias Prevention Atherosclerosis proposed by The Japan Society (JAS) Investigating Committee (1, 995-2, 000) under auspices JAS Board Directors.1) guideline defines diagnostic criteria serum total cholesterol (Table 1), LDL-cholesterol triglycerides 4) HDL-cholesterol 7). It also indicates desirable range initiation levels management 2) target treatment LDL-cholesterol.2) Though both are shown as atherogenic...

10.5551/jat.9.1 article EN cc-by-nc-sa Journal of Atherosclerosis and Thrombosis 2002-01-01

Abstract Ghrelin, an endogenous ligand for the GH secretagogue receptor 1a (GHS-R1a), was originally purified from rat stomach. Ghrelin mRNA and peptide have also been detected in hypothalamus pituitary. is a novel acylated that regulates release energy metabolism. GHS-R1a expressed pituitary gland as well several areas of brain including hypothalamus. In this study, we examined whether ghrelin could stimulate secretion feeding chronic GHRH, neuropeptide Y, agouti-related protein deficient...

10.1210/en.2002-220268 article EN Endocrinology 2002-08-29

To determine the prevalence of metabolic syndrome in Japanese general population, we analyzed data from a nationwide survey conducted 2000. According to new diagnostic criteria for 2005, 3,264 people aged 20 79 (men, 1,917; women, 1,347) total participants. The incidence was 7.8%. Men had higher (12.1%) than women (1.7%). Most satisfying were 50 years old or over, while men started rise their 30s. When applied Adult Treatment Panel III, about 3-fold higher. In this population visceral...

10.5551/jat.13.202 article EN cc-by-nc-sa Journal of Atherosclerosis and Thrombosis 2006-01-01

Hyperlipidemia is primarily implicated in the progression of coronary heart disease (CHD) and its treatment essential for patients with a history CHD. Statins such as simvastatin, lipid-lowering agents, are well-known their ability to normalize patient's serum lipid levels. The Japan Lipid Intervention Trial study simvastatin first nationwide investigation relationship between levels development CHD Japanese hypercholesterolemia. Of 5,127 patients, exclusively documented at enrollment, 4,673...

10.1253/circj.66.1096 article EN Circulation Journal 2002-01-01
Coming Soon ...